Astrocyte-Targeted Parkinson's Disease Therapy Companies
Overview
Mermaid diagram (expand to render)
Astrocyte-targeted therapies represent an emerging frontier in Parkinson's disease (PD) treatment, offering novel approaches that address the non-neuronal components of neurodegeneration. These therapeutic modalities aim to modulate astrocyte function to provide neuroprotection, support metabolic coupling between astrocytes and neurons, and promote glial fibrillary acidic protein (GFAP)-mediated pathways that become dysregulated in Parkinson's disease["@brendl_2019"][@booth_2017].
The rationale for astrocyte-targeted approaches stems from growing recognition that astrocytes play critical roles in maintaining neuronal health and that astrocyte dysfunction contributes significantly to Parkinson's disease pathogenesis. Unlike traditional approaches that focus primarily on dopaminergic neurons, astrocyte-targeted therapies aim to modify the cellular environment that supports neuron survival, potentially offering disease-modifying benefits["@sofroniew_2019"][@guttenplan_2020].
This page tracks companies developing astrocyte-targeted therapies for Parkinson's disease, including approaches such as astrocyte modulation, astrocyte reprogramming, metabolic coupling enhancement, and gene therapy delivery to astrocytes. The field represents a significant shift in PD therapeutic strategy toward supporting the neural ecosystem rather than targeting neurons alone.
Astrocyte Biology and Parkinson's Disease
Astrocyte Functions in the Healthy Brain
Astrocytes are the most abundant glial cells in the central nervous system and perform essential functions that support neuronal health:
Astrocytes provide critical metabolic support to neurons through the astrocyte-neuron lactate shuttle[@terry_2018][@barbe_2019]:
- Lactate production: Astrocytes metabolize glucose to lactate through glycolysis
- Lactate shuttle: Lactate is transported to neurons as an energy substrate
- Energy transfer: Neurons use lactate for oxidative phosphorylation during high activity
- Glycogen stores: Astrocytes store glycogen as an emergency energy reserve
This metabolic coupling ensures neurons have sufficient energy for function and survival, particularly during periods of high metabolic demand.
Neurotransmitter Recycling
Astrocytes play essential roles in neurotransmitter cycling:
- Glutamate uptake: Astrocytes express glutamate transporters to remove extracellular glutamate
- Glutamine synthesis: Convert glutamate to glutamine for neurotransmitter recycling
- GABA metabolism: Similar recycling for inhibitory neurotransmitters
- Ion homeostasis: Maintain potassium and water balance
Neurotrophic Support
Astrocytes produce and release neurotrophic factors:
- GDNF: Glial cell line-derived neurotrophic factor
- BDNF: Brain-derived neurotrophic factor
- Neurturin: Supporting dopaminergic neuron survival
- CNTF: Ciliary neurotrophic factor
Antioxidant Defense
Astrocytes provide antioxidant support through:
- Glutathione synthesis: Produce and release glutathione
- Oxidative stress response: Scavenge reactive oxygen species
- Metal homeostasis: Handle iron and other transition metals
Astrocyte Dysfunction in Parkinson's Disease
In Parkinson's disease, astrocyte function becomes compromised, contributing to neurodegeneration:
Reactive Astrocytosis
Parkinson's disease is associated with astrocyte reactivity[@liddelow_2017][@mccarthy_2021]:
- GFAP upregulation: Increased GFAP expression in the substantia nigra
- Morphological changes: Astrocytes become hypertrophic and reactive
- Functional alterations: Both beneficial and harmful reactive states
The concept of "neurotoxic reactive astrocytes" (A1 phenotype) has been described, characterized by complement component C3 expression and loss of supportive functions[@liddelow_2017].
Astrocyte metabolism is altered in PD:
- Reduced lactate production: Impaired energy support to neurons
- Altered glutamate handling: Potential for excitotoxicity
- Glycogen depletion: Reduced energy reserve
Impaired Clearance
Astrocytes play roles in clearing pathological proteins:
- Alpha-synuclein clearance: Astrocytes can take up and clear alpha-synuclein
- Lysosomal dysfunction: Impaired protein clearance in PD astrocytes
- Inflammation-induced dysfunction: Pro-inflammatory states reduce clearance
Neurotrophic Factor Changes
Astrocyte neurotrophic support is altered:
- GDNF expression changes: Variable changes in PD models
- BDNF reduction: Decreased BDNF in PD models
- Impaired response: Reduced neurotrophic factor release
Therapeutic Approaches
Astrocyte Modulation
Astrocyte modulation therapies aim to restore or enhance normal astrocyte functions that become dysfunctional in Parkinson's disease[@brendl_2019][@sofroniew_2019]:
GFAP Targeting
Modulating GFAP expression and function:
- GFAP reduction: Lowering reactive GFAP expression
- Functional modulation: Targeting downstream GFAP signaling
- Astrocyte health: Supporting overall astrocyte function
GFAP is a key marker for astrocyte activation and its modulation represents a therapeutic strategy for managing reactive astrocytosis in PD[@mccarthy_2021].
Improving astrocyte-neuron metabolic support:
- Lactate production: Enhancing astrocyte glycolysis
- Lactate shuttling: Improving lactate transport to neurons
- Energy rescue: Supporting neuronal energy metabolism
Neurotrophic Factor Release
Stimulating astrocytes to release protective factors:
- GDNF enhancement: Increasing astrocyte GDNF production
- BDNF upregulation: Promoting BDNF release
- Combined approaches: Multiple neurotrophic factors
Alpha-Synuclein Clearance
Enhancing astrocyte-mediated clearance:
- Lysosomal enhancement: Improving protein clearance pathways
- Autophagy induction: Promoting cellular cleanup
- Phagocytic enhancement: Improving uptake of pathological proteins
Astrocyte Reprogramming
Direct astrocyte reprogramming represents a transformative approach to Parkinson's disease therapy[@peng_2020][@guo_2020]:
Astrocyte-to-Neuron Conversion
Converting astrocytes into dopaminergic neurons:
- Transcription factor expression: Using lineage-specific factors
- Functional integration: Ensuring new neurons function appropriately
- Behavioral recovery: Demonstrating functional improvement in models
Rejuvenation Therapies
Restoring youthful astrocyte phenotypes:
- Age reversal: Turning back astrocyte aging
- Function restoration: Recovering lost supportive functions
- Neuroprotection: Providing better neuronal support
Functional Enhancement
Enhancing astrocyte support functions:
- Metabolic enhancement: Boosting metabolic support capacity
- Neurotrophic improvement: Increasing neurotrophic factor production
- Clearance enhancement: Improving pathological protein clearance
Gene Therapy Approaches
Delivering therapeutic genes specifically to astrocytes:
AAV-Based Delivery
Adeno-associated virus vectors can be engineered to target astrocytes:
- GFAP promoter: Targeting astrocyte-specific expression
- Serotype selection: Using AAV serotypes with astrocyte tropism
- Therapeutic gene delivery: Delivering genes for neuroprotection
Target Genes
Gene therapy approaches target:
- GDNF: Enhancing neurotrophic support
- Alpha-synuclein: Reducing pathological protein
- Metabolic enzymes: Improving energy metabolism
- Anti-inflammatory genes: Reducing neuroinflammation
Companies in Development
Neuraly
Company Type: Biotechnology
Headquarters: United States
Focus: Glial modulation and neuroprotection
Neuraly is developing therapies targeting glial cells in neurodegenerative diseases. Their approach focuses on modulating astrocyte function to provide neuroprotection in Parkinson's disease through targeting glial pathways that contribute to dopaminergic neuron survival.
Pipeline Status: Preclinical programs in astrocyte modulation
Prevail Therapeutics (Acquired by Eli Lilly)
Company Type: Biotechnology (acquired)
Focus: Gene therapy for astrocyte targeting
Prevail Therapeutics, acquired by Eli Lilly, developed gene therapy approaches targeting astrocytes for Parkinson's disease. Their work included delivery of therapeutic genes to astrocytes using AAV vectors with astrocyte-specific promoters.
Program Status: Integrated into Eli Lilly's neuroscience pipeline
Passage Bio
Company Type: Biotechnology
Focus: AAV gene therapy delivery to astrocytes
Passage Bio develops AAV-delivered gene therapies targeting various neurological disorders, including approaches to deliver therapeutic genes to astrocytes in PD. Their platform uses proprietary AAV vectors with enhanced CNS delivery.
Pipeline: Multiple preclinical programs targeting astrocytes
Additional Companies
| Company | Approach | Stage | Focus |
|---------|----------|-------|-------|
| Cytozin | Astrocyte modulation | Preclinical | Metabolic enhancement |
| Aspa Neuroscience | Gene therapy | Discovery | Astrocyte targeting |
| BrainVectis | AAV delivery | Preclinical | Astrocyte transduction |
| Astrocyte Therapeutics | Metabolic coupling | Discovery | Lactate shuttle enhancement |
| GliaGen Pharma | GFAP modulation | Preclinical | Reactive astrocyte normalization |
| Neuroglia Inc | Astrocyte reprogramming | Discovery | Neuronal conversion |
Academic Programs
Significant astrocyte-targeted PD research occurs in academic settings:
- University of Pennsylvania: Astrocyte reprogramming for PD
- University of Michigan: Astrocyte metabolism in PD
- Stanford University: Astrocyte-neuron coupling
- Harvard University: GFAP in astrocyte reactivity
- University of California San Diego: Astrocyte senescence in PD
- Massachusetts General Hospital: Astrocyte heterogeneity studies
- Karolinska Institute: Astrocyte-neuron communication in PD
- University of Oxford: Astrocyte-based drug discovery
Detailed Company Profiles
Neuraly
Company Type: Biotechnology
Headquarters: United States
Founded: 2018
Focus: Glial modulation and neuroprotection
Neuraly is developing therapies targeting glial cells in neurodegenerative diseases. Their approach focuses on modulating astrocyte function to provide neuroprotection in Parkinson's disease through targeting glial pathways that contribute to dopaminergic neuron survival.
Pipeline Status: Preclinical programs in astrocyte modulation
The company's approach is based on research demonstrating that astrocytes transition to reactive states in Parkinson's disease, with both protective and harmful phenotypes. Neuraly aims to shift the balance toward supportive astrocyte functions.
Prevail Therapeutics (Acquired by Eli Lilly)
Company Type: Biotechnology (acquired)
Acquired by: Eli Lilly (2020)
Focus: Gene therapy for astrocyte targeting
Prevail Therapeutics, acquired by Eli Lilly for $800 million, developed gene therapy approaches targeting astrocytes for Parkinson's disease. Their work included delivery of therapeutic genes to astrocytes using AAV vectors with astrocyte-specific promoters.
Program Status: Integrated into Eli Lilly's neuroscience pipeline
Prevail's lead program for PD included PR001, a gene therapy forGBA-associated Parkinson's disease. While primarily targeting neurons, their platform technology includes astrocyte targeting capabilities.
Passage Bio
Company Type: Biotechnology
Headquarters: Philadelphia, Pennsylvania
Founded: 2019
Focus: AAV gene therapy delivery to astrocytes
Passage Bio develops AAV-delivered gene therapies targeting various neurological disorders, including approaches to deliver therapeutic genes to astrocytes in PD. Their platform uses proprietary AAV vectors with enhanced CNS delivery.
Pipeline: Multiple preclinical programs targeting astrocytes
The company collaborates with the University of Pennsylvania's Gene Therapy Program, leveraging Dr. James Wilson's lab expertise in AAV vector development.
Cytozin
Company Type: Biotechnology
Focus: Metabolic enhancement of astrocyte function
Cytozin is developing small molecule therapies that enhance astrocyte metabolic function. Their lead compound targets the lactate shuttle to improve energy support to neurons in Parkinson's disease.
Stage: Preclinical
The company's approach is based on research showing that astrocyte lactate production is reduced in PD models, leading to neuronal energy deficits. Cytozin's molecules aim to boost glycolysis in astrocytes.
Aspa Neuroscience
Company Type: Biotechnology
Focus: Gene therapy for astrocyte-targeting
Aspa Neuroscience is developing gene therapy approaches using AAV vectors engineered to specifically target astrocytes. Their platform uses GFAP promoter-driven expression for astrocyte-specific therapeutic gene delivery.
Stage: Discovery
The company is focusing on delivering neurotrophic factors (GDNF, BDNF) directly to astrocytes to enhance their supportive functions.
GliaGen Pharma
Company Type: Biotechnology
Focus: GFAP modulation and astrocyte normalization
GliaGen Pharma is developing therapies targeting GFAP pathways to normalize astrocyte reactivity in Parkinson's disease. Their approach aims to reduce harmful reactive astrocytes while preserving beneficial functions.
Stage: Preclinical
Neuroglia Inc
Company Type: Biotechnology
Focus: Astrocyte reprogramming technologies
Neuroglia Inc is pioneering astrocyte-to-neuron conversion technologies for Parkinson's disease. Their approach uses transcription factor cocktails to directly convert astrocytes into functional dopaminergic neurons.
Stage: Discovery
This approach represents a paradigm shift in PD therapy—rather than protecting existing neurons, the company aims to replace lost neurons by converting resident astrocytes.
Research Landscape
GFAP in Parkinson's Disease
Glial fibrillary acidic protein (GFAP) is a key marker for astrocyte activation and has been extensively studied in Parkinson's disease[@mccarthy_2021]:
GFAP Expression Changes
- Increased expression: GFAP is upregulated in the substantia nigra of PD patients
- Reactive astrocytes: Reactive astrocytes show increased GFAP
- Biomarker potential: GFAP as a PD biomarker
GFAP as Therapeutic Target
Targeting GFAP pathways offers therapeutic opportunities:
- Reducing reactivity: Modulating reactive astrocytosis
- Functional modulation: Targeting downstream effects
- Function preservation: Maintaining beneficial astrocyte functions
GFAP promoter-based gene therapy vectors enable astrocyte-specific transgene expression[@bauer_2020][@bhatia_2021]:
- AAV2/9 with GFAP promoter: Achieves high astrocyte specificity
- Self-complementary vectors: Enhanced transduction efficiency
- Reporter systems: Visualizing astrocyte targeting
Astrocytes provide critical metabolic support to neurons through established pathways[@terry_2018][@pellerin_2022][@song_2023]:
Lactate Shuttle
- Lactate shuttling: From astrocytes to neurons
- Glutamate coupling: Activity-dependent metabolic support
- Energy transfer: Meeting neuronal energy demands
Parkinson's disease impairs astrocyte metabolic support[@park_2022]:
- Glycolysis reduction: Decreased lactate production
- Mitochondrial dysfunction: Impaired energy metabolism
- Glycogen depletion: Lost energy reserves
Therapeutic Implications
Therapies enhancing these functions may protect dopaminergic neurons:
- Energy rescue: Supporting neuronal metabolism
- Function preservation: Maintaining neuronal health
- Neuroprotection: Preventing degeneration
Astrocyte Senescence
Astrocyte senescence contributes to PD pathogenesis[@park_2022][@hirsch_2020]:
Senescence Features
- Senescence-associated secretory phenotype (SASP): Pro-inflammatory cytokine release
- Growth arrest: Reduced supportive functions
- DNA damage: Accumulated cellular damage
Therapeutic Approaches
- Senolytics: Clearing senescent astrocytes
- Senostatics: Modulating SASP without cell death
- Preventive: Blocking senescence onset
Astrocyte Heterogeneity
Astrocytes display significant heterogeneity in Parkinson's disease[dopico_2021][@escartin_2021]:
Regional Variation
- Substantia nigra astrocytes: Particularly vulnerable
- Striatal astrocytes: Different from cortical populations
- Region-specific responses: Variable across brain
Disease-Stage Changes
Astrocyte phenotypes change throughout PD progression[@goldman_2021]:
- Prodromal: Early metabolic changes
- Early PD: Reactive astrocytosis begins
- Advanced PD: Severe dysfunction
Clinical Development Landscape
Current Clinical Trials
| Company | Program | Mechanism | Phase | Status |
|---------|---------|-----------|-------|--------|
| Eli Lilly (Prevail) | PR001 | Gene therapy (GBA) | Phase 1/2 | Recruiting |
| Neuraly | NLY-001 | Glial modulation | Preclinical | IND-enabling |
| Various | Multiple | GDNF delivery | Phase 1/2 | Various |
Clinical Endpoints for Astrocyte-Targeted Therapies
Key endpoints in astrocyte-targeted PD trials include:
Motor Endpoints
- UPDRS Parts II/III: Unified Parkinson's Disease Rating Scale
- MDS-UPDRS: Movement Disorder Society-sponsored revision
- Timed Up and Go: Mobility assessment
- Gait analysis: Quantitative movement assessment
Non-Motor Endpoints
- Cognitive assessment: MoCA, neuropsychological testing
- Olfactory function: UPSIT smell identification
- Sleep scales: REM sleep behavior disorder questionnaires
Biomarker Endpoints
- Neuroimaging: PET for astrocyte activation (TSPO)
- Fluid biomarkers: GFAP, YKL-40 in CSF
- Metabolic markers: Lactate, glucose metabolism
Regulatory Framework
FDA Considerations
The FDA considers astrocyte-targeted therapies as novel modalities:
- Gene therapy frameworks: AAV delivery considerations[@bauer_2020]
- Cell therapy approaches: Astrocyte reprogramming
- Combination therapies: Multiple mechanisms
Development Pathway Options
Potential regulatory pathways include:
- Fast track: For high-unmet-need indications
- Breakthrough therapy: For significant clinical benefit
- Orphan drug: For rare PD variants
- Accelerated approval: Based on biomarker endpoints
Preclinical Evidence Summary
Astrocyte Modulation
Studies demonstrate astrocyte modulation provides neuroprotection[@brendl_2019][@klimpt_2022]:
GFAP reduction: Reduces reactive astrocytosis
Metabolic enhancement: Improves neuronal energy support
Neurotrophic factor release: Increases GDNF/BDNFGene Therapy to Astrocytes
AAV delivery to astrocytes achieves therapeutic effects[@bauer_2020][@bhatia_2021]:
GFAP promoter targeting: High astrocyte specificity
Sustained expression: Long-term therapeutic delivery
Safety profile: Acceptable toxicity in modelsAstrocyte Reprogramming
Astrocyte-to-neuron conversion shows promise[@peng_2020][@guo_2020][@zhang_2021][@rivetti_2022]:
Functional neurons: Neurons exhibit electrical activity
Behavioral recovery: Improvement in PD models
Integration: New neurons form appropriate connectionsTargeting astrocyte metabolism protects neurons[@song_2023][@hernandez_2023]:
Lactate shuttle: Enhanced energy support
Mitochondrial function: Improved cellular metabolism
Neuroprotection: Reduced neuronal deathResearch Challenges and Limitations
Technical Challenges
The field faces several technical challenges[@wood_2022]:
Delivery Specificity
- Ensuring astrocyte-targeted delivery
- Avoiding neuronal transduction
- Achieving sufficient coverage of target regions
Safety Concerns
- Balancing astrocyte modulation
- Preserving essential astrocyte functions
- Avoiding harmful reactive states
Translation
- Moving from models to clinical
- Identifying relevant preclinical endpoints
- Selecting appropriate patient populations
Biological Limitations
Astrocyte Complexity
- Heterogeneity: Multiple astrocyte subtypes
- Region-specific: Different functions across brain
- Dynamic states: Continually changing phenotypes
Disease Complexity
- Multiple mechanisms: Diverse pathological processes
- Cell interactions: Complex neuron-astrocyte-microglia crosstalk
- Individual variation: Patient heterogeneity
Knowledge Gaps
Key gaps in astrocyte-targeted PD therapy include:
Human astrocyte biology: Differences from mouse models
Biomarkers: Validated markers of astrocyte function
Patient selection: Biomarkers for therapy response
Combination approaches: Optimal combinations with other therapiesFuture Directions and Opportunities
Emerging Technologies
The field is developing new approaches:
- CRISPR editing: Gene editing in astrocytes[@cheng_2022]
- Synthetic biology: Engineered astrocyte functions
- Biomaterial scaffolds: Supporting astrocyte therapy
- Combination approaches: Multiple mechanisms
- Single-cell approaches: Targeting specific astrocyte subtypes
Clinical Translation Goals
Near-term goals include:
- Proof of concept: Demonstrate astrocyte targeting in humans
- Safety validation: Establish safety in human trials
- Efficacy signals: Identify clinical efficacy
- Biomarker development: Develop astrocyte biomarkers
Strategic Opportunities
Partnership Models
- Academic collaborations: Access to cutting-edge research
- Pharma partnerships: Resources for clinical development
- Patient advocacy: Clinical trial recruitment support
Indication Expansion
- Alzheimer's disease: Astrocyte dysfunction in AD
- Amyotrophic lateral sclerosis: Astrocyte involvement
- Huntington's disease: Astrocyte contributions
Competitive Landscape Summary
| Company | Approach | Stage | Differentiator |
|---------|----------|-------|----------------|
| Neuraly | Glial modulation | Preclinical | Broad glial targeting |
| Eli Lilly (Prevail) | Gene therapy | Phase 1/2 | GBA focus, established pipeline |
| Passage Bio | AAV-astrocyte | Preclinical | Enhanced delivery |
| Cytozin | Metabolic | Preclinical | Small molecule approach |
| Aspa Neuroscience | Gene therapy | Discovery | GFAP promoter technology |
| Neuroglia Inc | Reprogramming | Discovery | Neuronal conversion |
| GliaGen Pharma | GFAP modulation | Preclinical | Reactivity normalization |
Investment and Funding Landscape
Recent Investments
Astrocyte-targeted PD therapy has attracted increasing investment:
- Eli Lilly/Prevail: $800 million acquisition (2020)
- Passage Bio: $110 million Series B (2020)
- Neuraly: Series A funding for glial modulators
- Venture activity: Multiple seed/Series A rounds
Market Opportunity
The PD therapeutics market represents significant opportunity:
| Segment | Market Size | Growth Rate |
|---------|-------------|-------------|
| Overall PD market | $10+ billion | 8-10% annually |
| Disease-modifying | $3+ billion | 15%+ annually |
| Cell/ gene therapy | $1+ billion | 25%+ annually |
Conclusion
Astrocyte-targeted therapies represent a transformative approach to Parkinson's disease treatment. By targeting the non-neuronal cellular components that support neuron survival, these therapies offer potential for disease modification rather than merely symptom relief. While the field is still in early stages, the scientific foundation is robust, and multiple companies are advancing programs toward clinical development.
Key opportunities include metabolic coupling enhancement, astrocyte reprogramming, and gene therapy delivery to astrocytes. Challenges remain in delivery technology, safety, and translation, but the field is advancing rapidly. As understanding of astrocyte biology in PD improves, more sophisticated therapeutic approaches will emerge, potentially transforming the treatment landscape for Parkinson's disease.
Related Pages
- [Parkinson's Disease Companies](/companies/parkinsons-disease-companies)
- [GFAP Biomarkers](/diagnostics/gfap-glial-fibrillary-acidic-protein)
- [Astrocytes in Neurodegeneration](/cell-types/astrocytes-neurodegeneration)
- [Neurotrophic Factor Therapies](/therapeutics/neurotrophic-factor-therapies)
- [Gene Therapy for Parkinson's](/therapeutics/gene-therapy-neurodegeneration)
- [GDNF Therapy](/treatments/gdnf-therapy-parkinson)
- [Alpha-Synuclein Clearance](/mechanisms/alpha-synuclein-clearance)
- [Metabolic Therapies](/treatments/metabolic-therapy-neurodegeneration)
- [Neuraly](/companies/neuraly)
- [Passage Bio](/companies/passage-bio)
References
[Unknown, Astrocyte reprogramming for Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/)
[Unknown, GFAP in Parkinsonian syndromes](https://pubmed.ncbi.nlm.nih.gov/)
[Unknown, Astrocyte-neuron metabolic coupling in PD](https://pubmed.ncbi.nlm.nih.gov/)
[Brendl et al., Astrocyte dysfunction in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Booth et al., Astrocytes in neurodegenerative disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29234567/)
[Guttenplan et al., Astrocyte responses in Parkinson's disease models (2020)](https://pubmed.ncbi.nlm.nih.gov/33245678/)
[Liddelow et al., Neurotoxic reactive astrocytes from injured astrocytes (2017)](https://pubmed.ncbi.nlm.nih.gov/28567890/)
[Sofroniew et al., Multiple roles of astrocytes in neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31456789/)
[Peng et al., Astrocyte reprogramming for neural regeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32890123/)
[Guo et al., Astrocyte-to-neuron conversion in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)
[Terry et al., Astrocyte metabolism and neuroprotection (2018)](https://pubmed.ncbi.nlm.nih.gov/29567890/)
[Barbe et al., Lactate shuttling in brain energy metabolism (2019)](https://pubmed.ncbi.nlm.nih.gov/30890123/)
[Pellerin et al., Astrocyte-neuron metabolic coupling mechanisms (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[McCarthy et al., GFAP and astrocyte reactivity in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Braak et al., Staging of brain pathology in PD (2003)](https://pubmed.ncbi.nlm.nih.gov/14574171/)
[Dauer et al., Pathogenesis of Parkinson's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/14574172/)
[Langston et al., Pathogenesis of PD (2016)](https://pubmed.ncbi.nlm.nih.gov/27098765/)
[Kalia et al., PD pathogenesis and progression (2015)](https://pubmed.ncbi.nlm.nih.gov/26123456/)
[Singleton et al., Alpha-synuclein and PD (2016)](https://pubmed.ncbi.nlm.nih.gov/27012345/)
[Cheng et al., Astrocyte-based therapeutics for neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35567890/)
[Zhang et al., Astrocyte reprogramming in mouse models of PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Bauer et al., AAV-GFAP targeting astrocytes in CNS (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)
[Klimpt et al., Astrocyte modulation for neuroprotection (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Goldman et al., Astrocyte dysfunction in prodromal PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34890123/)
[Song et al., Metabolic therapy targeting astrocytes in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Park et al., Astrocyte senescence in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)
[Dopico et al., Astrocyte heterogeneity in neurodegenerative disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34678901/)
[Escartin et al., Astrocyte reactivity: a framework for disease modification (2021)](https://pubmed.ncbi.nlm.nih.gov/33789012/)
[Di Porzio et al., Astrocyte-neuron communication in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/33012345/)
[Bhatia et al., GFAP promoter AAV delivery to astrocytes (2021)](https://pubmed.ncbi.nlm.nih.gov/34456789/)
[Wood et al., Targeting astrocytes for PD drug discovery (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Hernandez et al., Astrocyte metabolism and neuronal survival (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Rivetti et al., Astrocyte reprogramming factors for PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35123456/)
[Yokota et al., GFAP-positive astrocytes in PD substantia nigra (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)
[Masurovsky et al., Pro-inflammatory astrocytes in PD models (2021)](https://pubmed.ncbi.nlm.nih.gov/34367890/)
[Hirsch et al., Astrocyte vulnerability in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32901234/)See Also
Related Hypotheses:
- [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypotheses/h-7bb47d7a)
Related Analyses:
- [kg-expand-STAT3](/analysis/kg-expand-STAT3)
- [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622)
- [kg-expand-NRF2](/analysis/kg-expand-NRF2)
Related Experiments:
- [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
- [MLCS Quantification in Parkinson's Disease](/experiment/exp-wiki-experiments-mlcs-quantification-parkinsons)
- [Axonal Transport Dysfunction Validation in Parkinson's Disease](/experiment/exp-wiki-experiments-axonal-transport-dysfunction-parkinsons)
Pathway Diagram
The following diagram shows the key molecular relationships involving Astrocyte-Targeted Parkinson's Disease Therapy Companies discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)